Lantern Pharma Inc (NASDAQ:LTRN) — Market Cap & Net Worth
Market Cap & Net Worth: Lantern Pharma Inc (LTRN)
Lantern Pharma Inc (NASDAQ:LTRN) has a market capitalization of $22.50 Million ($22.50 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #24818 globally and #5293 in its home market, demonstrating a 4.89% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Lantern Pharma Inc's stock price $1.93 by its total outstanding shares 12784146 (12.78 Million). Also see LTRN asset base for a full breakdown of the balance sheet.
Lantern Pharma Inc Market Cap History: 2020 to 2026
Lantern Pharma Inc's market capitalization history from 2020 to 2026. Data shows change from $246.09 Million to $24.67 Million (-27.86% CAGR). Also see Lantern Pharma Inc (LTRN) cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Lantern Pharma Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.00% | #705 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #2317 of 3165 |
Weight: Lantern Pharma Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Lantern Pharma Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Lantern Pharma Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check current stock price of Lantern Pharma Inc for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of LTRN by Market Capitalization
Companies near Lantern Pharma Inc in the global market cap rankings as of September 18, 2026. Review Lantern Pharma Inc tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Lantern Pharma Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Lantern Pharma Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Lantern Pharma Inc's market cap moved from $246.09 Million to $ 24.67 Million, with a yearly change of -27.86%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $24.67 Million | -36.30% |
| 2025 | $38.74 Million | -5.02% |
| 2024 | $40.78 Million | -25.47% |
| 2023 | $54.72 Million | -29.14% |
| 2022 | $77.22 Million | -24.31% |
| 2021 | $102.02 Million | -58.55% |
| 2020 | $246.09 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Lantern Pharma Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $22.50 Million USD |
| MoneyControl | $22.50 Million USD |
| MarketWatch | $22.50 Million USD |
| marketcap.company | $22.50 Million USD |
| Reuters | $22.50 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Lantern Pharma Inc
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1a clinical trial for the treatment of advanced or metastatic solid tumors, or unresectable or recurrent GBM, solid tumor,… Read more